IDH wild-type grade 2 diffuse astrocytomas: prognostic factors and impact of treatments within molecular subgroups.
Rudà R, Bruno F, Ius T, Silvani A, Minniti G, Pace A, Lombardi G, Bertero L, Pizzolitto S, Pollo B, Conti Nibali M, Pellerino A, Migliore E, Skrap M, Bello L, Soffietti R.
Rudà R, et al. Among authors: pace a.
Neuro Oncol. 2022 May 4;24(5):809-820. doi: 10.1093/neuonc/noab239.
Neuro Oncol. 2022.
PMID: 34651653
Free PMC article.